C. R. Dorn, D. O. Taylor, F. L. Frye, and H. H. Hibbard, Survey of animal neoplasms in alameda and contra Costa counties, California. I. Methodology and description of cases, J Natl Cancer Inst, vol.40, pp.295-305, 1968.

R. Brodey, Canine and feline neoplasia, Adv Vet Sci Comp Med, vol.14, pp.309-54, 1970.

D. W. Hayden and S. W. Nielsen, Feline mammary tumours, J Small AnimPract, vol.12, pp.687-98, 1971.

M. Castagnaro, C. Casalone, E. Bozzetta, D. Maria, R. Biolatti et al., Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas, J Comp Pathol, vol.119, pp.263-75, 1998.

M. Castagnaro, C. Casalone, G. Ru, G. C. Nervi, E. Bozzetta et al., Argyrophilic nucleolar organiser regions (AgNORs) count as indicator of post-surgical prognosis in feline mammary carcinomas, Res Vet Sci, vol.64, pp.97-100, 1998.

M. Castagnaro, D. Maria, R. Bozzetta, E. Ru, G. Casalone et al., Ki-67 index as indicator of the post-surgical prognosis in feline mammary carcinomas, Res Vet Sci, vol.65, pp.223-229, 1998.

T. Ito, T. Kadosawa, M. Mochizuki, S. Matsunaga, R. Nishimura et al., Prognosis of malignant mammary tumor in 53 cats, J Vet Med Sci, vol.58, pp.723-729, 1996.

F. Millanta, M. Calandrella, S. Citi, D. Santa, D. Poli et al., Overexpression of HER-2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential, Vet Pathol, vol.42, pp.30-34, 2005.

F. Seixas, C. Palmeira, M. A. Pires, M. J. Bento, and C. Lopes, Grade is an independent prognostic factor for feline mammary carcinomas: a clinicopathological and survival analysis, Vet J, vol.187, pp.65-71, 2011.

B. Brunetti, P. Asproni, G. Beha, L. V. Muscatello, F. Millanta et al., Molecular phenotype in mammary tumours of queens: correlation between primary tumour and lymph node metastasis, J Comp Pathol, vol.148, pp.206-219, 2013.

G. P. Burrai, S. I. Mohammed, M. A. Miller, V. Marras, S. Pirino et al., Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor-and progesterone receptor negative breast lesions, BMC Cancer, vol.10, p.156, 2010.

D. Caliari, V. Zappulli, R. Rasotto, B. Cardazzo, F. Frassineti et al., Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer, BMC Vet Res, vol.10, p.185, 2014.

E. Dagher, J. Abadie, D. Loussouarn, D. Fanuel, M. Campone et al., Bcl-2 expression and prognostic significance in feline invasive mammary carcinomas: a retrospective observational study, BMC Vet Res, vol.15, p.25, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-01991065

R. De-maria, M. Olivero, S. Iussich, M. Nakaichi, T. Murata et al., Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer, Cancer Res, vol.65, pp.907-919, 2005.

F. Millanta, M. Calandrella, I. Vannozzi, and A. Poli, Steroid hormone receptors in normal, dysplastic and neoplastic feline mammary tissues and their prognostic significance, Vet Rec, vol.158, pp.821-825, 2006.

R. Rasotto, D. Caliari, M. Castagnaro, R. Zanetti, and V. Zappulli, An immunohistochemical study of HER-2 expression in feline mammary tumours, J Comp Pathol, vol.144, pp.170-179, 2011.

M. Soares, J. Correia, P. Rodrigues, M. Simões, D. Matos et al., Feline HER2 protein expression levels and gene status in feline mammary carcinoma: optimization of immunohistochemistry (IHC) and in situ hybridization (ISH) techniques, Microsc Microanal, vol.19, pp.876-82, 2013.

M. Soares, J. Correia, M. C. Peleteiro, and F. Ferreira, St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study, Tumour Biol, vol.37, pp.4053-64, 2016.

D. A. Wiese, T. Thaiwong, V. Yuzbasiyan-gurkan, and M. Kiupel, Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype, BMC Cancer, vol.13, p.403, 2013.

B. D. Lehmann, J. A. Bauer, X. Chen, M. E. Sanders, A. B. Chakravarthy et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J Clin Invest, vol.121, pp.2750-67, 2011.

B. D. Lehmann, B. Jovanovi?, X. Chen, M. V. Estrada, K. N. Johnson et al., Refinement of triple-negative breast Cancer molecular subtypes: implications for Neoadjuvant chemotherapy selection, PLoS One, vol.11, p.157368, 2016.

M. D. Burstein, A. Tsimelzon, G. M. Poage, K. R. Covington, A. Contreras et al., Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer, Clin Cancer Res, vol.21, pp.1688-98, 2015.

P. Jézéquel, D. Loussouarn, C. Guérin-charbonnel, L. Campion, A. Vanier et al., Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response, Breast Cancer Res, vol.17, p.43, 2015.

P. Jézéquel, O. Kerdraon, H. Hondermarck, C. Guérin-charbonnel, H. Lasla et al., Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications, Breast Cancer Res, vol.21, p.65, 2019.

M. Katoh, M. Igarashi, H. Fukuda, H. Nakagama, and M. Katoh, Cancer genetics and genomics of human FOX family genes, Cancer Lett, vol.328, pp.198-206, 2013.

J. S. Carroll, X. S. Liu, A. S. Brodsky, W. Li, C. A. Meyer et al., Chromosomewide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1, Cell, vol.122, pp.33-43, 2005.

J. L. Robinson, S. Macarthur, C. S. Ross-innes, W. D. Tilley, D. E. Neal et al., Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1, EMBO J, vol.30, pp.3019-3046, 2011.

S. Guiu, C. Charon-barra, D. Vernerey, P. Fumoleau, M. Campone et al., Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial, Future Oncol, vol.11, pp.2283-97, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02168431

K. Astvatsaturyan, Y. Yue, A. E. Walts, and S. Bose, Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features, PLoS One, vol.13, p.197827, 2018.

T. Moriya, N. Kanomata, Y. Kozuka, M. Fukumoto, N. Iwachido et al., Usefulness of immunohistochemistry for differential diagnosis between benign and malignant breast lesions, Breast Cancer, vol.16, pp.173-181, 2009.

M. M. Shamloula, S. H. El-shorbagy, and E. M. Saied, P63 and cytokeratin8/18 expression in breast, atypical ductal hyperplasia, ductal carcinoma in situ and invasive duct carcinoma, J Egypt Natl Canc Inst, vol.19, pp.202-212, 2007.

F. Chocteau, M. M. Boulay, F. Besnard, G. Valeau, D. Loussouarn et al., Proposal for a Histological Staging System of Mammary Carcinomas in Dogs and Cats. Part 2: Feline Mammary Carcinomas, Front Vet Sci, vol.6, p.387, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02383102

E. Dagher, J. Abadie, D. Loussouarn, M. Campone, and F. Nguyen, Feline Invasive Mammary Carcinomas: Prognostic Value of Histological Grading, Vet Pathol, vol.56, issue.5, pp.660-70, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02167919

C. W. Elston and I. O. Ellis, Pathological prognostic factors in breast cancer: I. the value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathol, vol.19, pp.403-413, 1991.

J. Morris, Mammary tumors in the cat: size matters, so early intervention saves lives, J Feline Med Surg, vol.15, pp.391-400, 2013.

L. N. Owen, World Health Organization. Veterinary public health unit & WHO collaborating Center for Comparative Oncology, 1980.

C. Peñafiel-verdu, A. J. Buendia, J. A. Navarro, G. A. Ramirez, M. Vilafranca et al., Reduced expression of E-cadherin and ?-catenin and high expression of basal cytokeratins in feline mammary carcinomas with regional metastasis, Vet Pathol, vol.49, pp.979-87, 2012.

A. Gama, A. Alves, and F. Schmitt, Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification, Virchows Arch, vol.453, pp.123-155, 2008.

S. Guil-luna, R. Sánchez-céspedes, Y. Millán, D. Andrés, F. J. Rollón et al., Aglepristone decreases proliferation in progesterone receptorpositive canine mammary carcinomas, J Vet Intern Med, vol.25, pp.518-541, 2011.

F. Nguyen, L. Peña, C. Ibisch, D. Loussouarn, A. Gama et al., Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors, Breast Cancer Res Treat, vol.167, pp.635-683, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01629625

M. Yi, L. Huo, K. B. Koenig, E. A. Mittendorf, F. Meric-bernstam et al., Which threshold for ER positivity? A retrospective study based on 9639 patients, Ann Oncol, vol.25, pp.1004-1015, 2014.

M. Ono, H. Tsuda, M. Yunokawa, K. Yonemori, C. Shimizu et al., Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers, Breast Cancer, vol.22, pp.141-52, 2015.

A. C. Wolff, M. E. Hammond, D. G. Hicks, M. Dowsett, L. M. Mcshane et al., Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, J Clin Oncol, vol.31, pp.3997-4013, 2013.

H. A. Alshenawy, Prevalence of androgen receptors in invasive breast carcinoma and its relation with estrogen receptor, progesterone receptor and Her2/neu expression, J Egypt Natl Canc Inst, vol.24, pp.77-83, 2012.

K. Elebro, S. Borgquist, M. Simonsson, A. Markkula, K. Jirström et al., Combined androgen and estrogen receptor status in breast Cancer: treatment prediction and prognosis in a population-based prospective cohort, Clin Cancer Res, vol.21, pp.3640-50, 2015.

K. Elebro, S. Butt, M. Dorkhan, H. Jernström, and S. Borgquist, Age at first childbirth and oral contraceptive use are associated with risk of androgen receptornegative breast cancer: the Malmö diet and Cancer cohort, Cancer Causes Control, vol.25, pp.945-57, 2014.

L. O. Gonzalez, M. D. Corte, J. Vazquez, S. Junquera, R. Sanchez et al., Androgen receptor expression in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors, BMC Cancer, vol.8, p.149, 2008.

R. Hu, S. Dawood, M. D. Holmes, L. C. Collins, S. J. Schnitt et al., Androgen receptor expression and breast cancer survival in postmenopausal women, Clin Cancer Res, vol.17, pp.1867-74, 2011.

L. A. Niemeier, D. J. Dabbs, S. Beriwal, J. M. Striebel, and R. Bhargava, Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation, Mod Pathol, vol.23, pp.205-217, 2010.

Y. Ogawa, H. E. Matsumoto, K. Ikeda, K. Tokunaga, S. Nagahara et al., Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers, Int J Clin Oncol, vol.13, pp.431-436, 2008.

S. Park, J. S. Koo, M. S. Kim, H. S. Park, J. S. Lee et al., Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers, Ann Oncol, vol.22, pp.1755-62, 2011.

Y. Hisamatsu, E. Tokunaga, N. Yamashita, S. Akiyoshi, S. Okada et al., Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer, Ann Surg Oncol, vol.19, pp.1145-52, 2012.

M. Kawase, T. Toyama, S. Takahashi, S. Sato, N. Yoshimoto et al., FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer, Breast Cancer, vol.22, pp.308-324, 2015.

M. Sasahara, A. Matsui, Y. Ichimura, Y. Hirakata, Y. Murata et al., Overexpression of androgen receptor and Forkhead-box A1 protein in apocrine breast carcinoma, Anticancer Res, vol.34, pp.1261-1268, 2014.

N. Tominaga, Y. Naoi, K. Shimazu, T. Nakayama, N. Maruyama et al., Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy, Ann Oncol, vol.23, pp.3051-3058, 2012.

A. Albergaria, J. Paredes, B. Sousa, F. Milanezi, V. Carneiro et al., Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours, Breast Cancer Res, vol.11, p.40, 2009.

S. Badve, D. Turbin, M. A. Thorat, A. Morimiya, T. O. Nielsen et al., FOXA1 expression in breast cancer--correlation with luminal subtype a and survival, Clin Cancer Res, vol.13, pp.4415-4436, 2007.

H. O. Habashy, D. G. Powe, E. A. Rakha, G. Ball, C. Paish et al., Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance, Eur J Cancer, vol.44, pp.1541-51, 2008.

Y. Hisamatsu, E. Tokunaga, N. Yamashita, S. Akiyoshi, S. Okada et al., Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer, Breast Cancer, vol.22, pp.520-528, 2015.

Y. Horimoto, A. Arakawa, N. Harada-shoji, H. Sonoue, Y. Yoshida et al., Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases, Br J Cancer, vol.112, pp.345-51, 2015.

M. Hosoda, M. Yamamoto, K. Nakano, K. C. Hatanaka, E. Takakuwa et al., Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre-and postmenopausal women with estrogen receptorpositive breast cancer, Breast Cancer Res Treat, vol.144, pp.249-61, 2014.

Q. Hu, Z. Luo, T. Xu, J. Y. Zhang, Y. Zhu et al., FOXA1: a promising prognostic marker in breast cancer, Asian Pac J Cancer Prev, vol.15, pp.11-17, 2014.

J. Y. Tsang, Y. B. Ni, S. K. Chan, M. M. Shao, B. K. Law et al., Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers, Ann Surg Oncol, vol.21, pp.2218-2246, 2014.

I. Mrkli?, Z. Pogoreli?, V. Capkun, and S. Tomi?, Expression of androgen receptors in triple negative breast carcinomas, Acta Histochem, vol.115, pp.344-352, 2013.

E. A. Rakha, M. E. El-sayed, A. R. Green, A. H. Lee, J. F. Robertson et al., Prognostic markers in triple-negative breast cancer, Cancer, vol.109, pp.25-32, 2007.

D. Tang, S. Xu, Q. Zhang, and W. Zhao, The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer, Med Oncol, vol.29, pp.526-559, 2012.

K. Weijer and A. A. Hart, Prognostic factors in feline mammary carcinoma, J Natl Cancer Inst, vol.70, pp.709-725, 1983.

F. Gujam, K. Dickson, P. Mccall, D. Mcmillan, and J. Edwards, The relationship between androgen receptor. Components Tumour Microenvironment Surviv Breast Cancer Mol Subtypes Canc Ther, Oncol Int J, vol.11, p.555814, 2018.

R. J. Mehta, R. K. Jain, S. Leung, J. Choo, T. Nielsen et al., FOXA1 is an independent prognostic marker for ER-positive breast cancer, Breast Cancer Res Treat, vol.131, pp.881-90, 2012.

J. Shou, Y. Lai, J. Xu, and J. Huang, Prognostic value of FOXA1 in breast cancer: a systematic review and meta-analysis, Breast, vol.27, pp.35-43, 2016.

I. Wolf, S. Bose, E. A. Williamson, C. W. Miller, B. Y. Karlan et al., FOXA1: growth inhibitor and a favorable prognostic factor in human breast cancer, Int J Cancer, vol.120, pp.1013-1035, 2007.

M. A. Thorat, C. Marchio, A. Morimiya, K. Savage, H. Nakshatri et al., Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis, J Clin Pathol, vol.61, pp.327-359, 2008.

K. He, H. Zeng, X. Xu, A. Li, Q. Cai et al., Clinicopathological significance of forkhead box protein A1 in breast cancer: a meta-analysis, Exp Ther Med, vol.11, pp.2525-2555, 2016.

N. Rangel, N. Fortunati, S. Osella-abate, L. Annaratone, C. Isella et al., FOXA1 and AR in invasive breast cancer: new findings on their coexpression and impact on prognosis in ER-positive patients, BMC Cancer, vol.18, p.703, 2018.

M. A. Pratt, Paradoxical roles for FOXA1 in anti-estrogen resistance and as a luminal differentiation factor in breast cancer, Gland Surg, vol.1, pp.9-11, 2012.

J. L. Robinson and J. S. Carroll, FoxA1 is a key mediator of hormonal response in breast and prostate cancer, Front Endocrinol (Lausanne), vol.3, p.68, 2012.

Q. Yu, Y. Niu, N. Liu, J. Z. Zhang, T. J. Liu et al., Expression of androgen receptor in breast cancer and its significance as a prognostic factor, Ann Oncol, vol.22, pp.1288-94, 2011.

J. He, R. Peng, Z. Yuan, S. Wang, J. Peng et al., Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray, Med Oncol, vol.29, pp.406-416, 2012.

T. Maeda, Y. Nakanishi, Y. Hirotani, F. Fuchinoue, K. Enomoto et al., Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer, Med Mol Morphol, vol.49, pp.11-21, 2016.

N. Liu, Y. Niu, S. L. Wang, Q. Yu, R. J. Zhang et al., Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas

, Zhonghua Yi Xue Za Zhi, vol.90, pp.1403-1410, 2010.

A. Prat, B. Adamo, M. C. Cheang, C. K. Anders, L. A. Carey et al., Molecular characterization of basal-like and non-basal-like triple-negative breast cancer, Oncologist, vol.18, pp.123-156, 2013.

K. D. Yu, R. Zhu, M. Zhan, A. A. Rodriguez, W. Yang et al., Identification of prognosis-relevant subgroups in patients with chemoresistant triplenegative breast cancer, Clin Cancer Res, vol.19, pp.2723-2756, 2013.

H. Masuda, K. A. Baggerly, Y. Wang, Y. Zhang, A. M. Gonzalez-angulo et al., Differential response to neoadjuvant chemotherapy among 7 triplenegative breast cancer molecular subtypes, Clin Cancer Res, vol.19, pp.5533-5573, 2013.

S. Guiu, C. Mollevi, C. Charon-barra, F. Boissière, E. Crapez et al., Prognostic value of androgen receptor and FOXA1 co-expression in nonmetastatic triple negative breast cancer and correlation with other biomarkers, Br J Cancer, vol.119, pp.76-85, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02289193

, Publisher's Note

, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations